CTI BioPharma Corp. (CTIC)
$9.095
+0.01 (+0.06%)
Rating:
Recommendation:
Neutral
| Symbol | CTIC |
|---|---|
| Price | $9.095 |
| Beta | 0.831 |
| Volume Avg. | 5.66M |
| Market Cap | 1.199B |
| Shares () | - |
| 52 Week Range | 4.01-9.1 |
| 1y Target Est | - |
| DCF Unlevered | CTIC DCF -> | |
|---|---|---|
| DCF Levered | CTIC LDCF -> | |
| ROE | 473.67% | Strong Buy |
| ROA | -68.60% | Strong Sell |
| Operating Margin | - | |
| Debt / Equity | -192.90% | Sell |
| P/E | -16.84 | Strong Sell |
| P/B | -47.21 | Strong Sell |
Latest CTIC news
About
Download (Excel)Dr. Adam R. Craig M.B.A., M.D., Ph.D.
Healthcare
Biotechnology
NASDAQ Capital Market
CTI BioPharma Corp., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States. It offers VONJO (pacritinib), an investigational oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R for the treatment of adult patients with myelofibrosis. It has license and collaboration agreement with Teva Pharmaceutical Industries Ltd.; S*BIO Pte Ltd.; and Baxalta. The company was formerly known as Cell Therapeutics, Inc. and changed its name to CTI BioPharma Corp. in May 2014. CTI BioPharma Corp. was incorporated in 1991 and is headquartered in Seattle, Washington.